Towards irreversible HIV inactivation: Stable gp120 binding by nucleophilic antibodies

Journal of Molecular Recognition

Volumn 19, Issue 5, 2006, Pages 423-431

  Nishiyama, Yasuhiro ^a   Karle, Sangeeta ^a   Mitsuda, Yukie ^a   Taguchi, Hiroaki ^a   Planque, Stephanie ^a   Salas, Maria ^b   Hanson, Carl ^b   Paul, Sudhir ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b VIRAL AND RICKETTSIAL DISEASE LABORATORY   (United States)

Author keywords

gp120; HIV; Nucleophilic antibody

Indexed keywords

DODECYL SULFATE SODIUM; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; MONOCLONAL ANTIBODY;

ANIMAL; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CHEMISTRY; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOLOGY; KINETICS; METABOLISM; MOUSE; PROTEIN BINDING; SERODIAGNOSIS; THERMODYNAMICS; VIRUS INACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-ANTIBODY COMPLEX; HIV; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; KINETICS; MICE; NEUTRALIZATION TESTS; PROTEIN BINDING; SODIUM DODECYL SULFATE; THERMODYNAMICS; VIRUS INACTIVATION;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 33748931667     PISSN: 09523499     EISSN: 10991352     Source Type: Journal    
DOI: 10.1002/jmr.795     Document Type: Article

References (26)

1. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR. 2004. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78: 13232-13252.
2. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, Sawyer LS, Hendry RM, Dunlop N, Nara PL, Lamacchia M, Garratty E, Stiehm ER, Bryson YJ, Cao Y, Moore JP, Ho DD, Barbas CFIII. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266: 1024-1027.
3. Burton DR, Montefiori DC. 1997. The antibody response in HIV-1 infection. AIDS 11 (Suppl. A): S87-98.
4. Burton DR, Moore JP. 1998. Why do we not have an HIV vaccine and how can we make one? Nat. Med. 4: 495-498.
5. Chilkoti A, Stayton PS. 1995. Molecular origins of the slow streptavidin-biotin dissociation kinetics. J. Am. Chem. Soc. 117: 10622-10628.
6. Cormier EG, Dragic T. 2002. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J. Virol. 76: 8953-8957.
7. Gao QS, Sun M, Tyutyulkova S, Webster D, Rees A, Tramontano A, Massey RJ, Paul S. 1994. Molecular cloning of a proteolytic antibody light chain. J. Biol. Chem. 269: 32389-32393.
8. Gorny MK, Xu JY, Gianakakos V, Karwowska S, Williams C, Sheppard HW, Hanson CV, Zolla-Pazner S. 1991. Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. Proc. Natl. Acad. Sci. U.S.A. 88: 3238-3242.
9. Gorny MK, Xu JY, Karwowska S, Buchbinder A, Zolla-Pazner S. 1993. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J. Immunol. 150: 635-643.
10. Hedstrom L. 2002. Serine protease mechanism and specificity. Chem. Rev. 102: 4501-4524.
11. Karle S, Planque S, Nishiyama Y, Taguchi H, Zhou YX, Salas M, Lake D, Thiagarajan P, Arnett F, Hanson CV, Paul S. 2004. Cross-clade HIV-1 neutralization by an antibody fragment from a lupus phage display library. AIDS 18: 329-331.
12. Kent KA, Robinson J. 1996. Antigenic determinants on HIV-1 envelope glycoproteins: a dickens of a time with oligomer twist. AIDS 10 (Suppl. A): S107-114.
13. Lacroix-Desmazes S, Moreau A, Sooryanarayana, Bonnemain C, Stieltjes N, Pashov A, Sultan Y, Hoebeke J, Kazatchkine MD, Kaveri SV. 1999. Catalytic activity of antibodies against factor VIII in patients with hemophilia A. Nat. Med. 5: 1044-1047.
14. Lefevre S, Debat H, Thomas D, Friboulet A, Avalle B. 2001. A suicide-substrate mechanism for hydrolysis of beta-lactams by an anti-idiotypic catalytic antibody. FEBS Lett. 489: 25-28.
15. Nishiyama Y, Bhatia G, Bangale Y, Planque S, Mitsuda Y, Taguchi H, Karle S, Paul S. 2004. Toward selective covalent inactivation of pathogenic antibodies: a phosphate diester analog of vasoactive intestinal peptide that inactivates catalytic autoantibodies. J. Biol. Chem. 279: 7877-7883.
16. Nishiyama Y, Mitsuda Y, Taguchi H, Planque S, Hara M, Karle S, Hanson CV, Uda T, Paul S. 2005. Broadly distributed nucleophilic reactivity of proteins coordinated with specific ligand binding activity. J. Mol. Recognit. 18: 295-306.
17. Oleksyszyn J, Powers JC. 1994. Amino acid and peptide phosphonate derivatives as specific inhibitors of serine peptidases. Methods Enzymol. 244: 423-441.
18. Paul S, Johnson DR, Massey R. 1991. Binding and multiple hydrolytic sites in epitopes recognized by catalytic anti-peptide antibodies. Ciba. Found. Symp. 159: 156-167.
19. Paul S, Volle DJ, Beach CM, Johnson DR, Powell MJ, Massey RJ. 1989. Catalytic hydrolysis of vasoactive intestinal peptide by human autoantibody. Science 244: 1158-1162.
20. Paul S, Planque S, Zhou YX, Taguchi H, Bhatia G, Karle S, Hanson C, Nishiyama Y. 2003. Specific HIV gp120-cleaving antibodies induced by covalently reactive analog of gp120. J. Biol. Chem. 278: 20429-20435.
21. Piran U, Riordan WJ. 1990. Dissociation rate constant of the biotin-streptavidin complex. J. Immunol. Methods 133: 141-143.
22. Planque S, Taguchi H, Burr G, Bhatia G, Karle S, Zhou YX, Nishiyama Y, Paul S. 2003. Broadly Distributed Chemical Reactivity of Natural Antibodies Expressed in Coordination with Specific Antigen Binding Activity. J. Biol. Chem. 278: 20436-20443.
23. Planque S, Bangale Y, Song XT, Karle S, Taguchi H, Poindexter B, Bick R, Edmundson A, Nishiyama Y, Paul S. 2004. Ontogeny of proteolytic immunity: IgM serine proteases. J. Biol. Chem. 279: 14024-14032.
24. Shuster AM, Gololobov GV, Kvashuk OA, Bogomolova AE, Smirnov IV, Gabibov AG. 1992. DNA hydrolyzing autoantibodies. Science 256: 665-667.
25. VanCott TC, Bethke FR, Polonis VR, Gorny MK, Zolla-Pazner S, Redfield RR, Birx DL. 1994. Dissociation rate of antibody-gp120 binding interactions is predictive of V3-mediated neutralization of HIV-1. J. Immunol. 153: 449-459.
26. Zhou GW, Guo J, Huang W, Fletterick RJ, Scanlan TS. 1994. Crystal structure of a catalytic antibody with a serine protease active site. Science 265: 1059-1064.